These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

612 related items for PubMed ID: 11331613

  • 21. Role of VHL gene mutation in human cancer.
    Kim WY, Kaelin WG.
    J Clin Oncol; 2004 Dec 15; 22(24):4991-5004. PubMed ID: 15611513
    [Abstract] [Full Text] [Related]

  • 22. Von Hippel-Lindau tumor suppressor protein and hypoxia-inducible factor in kidney cancer.
    Maynard MA, Ohh M.
    Am J Nephrol; 2004 Dec 15; 24(1):1-13. PubMed ID: 14654728
    [Abstract] [Full Text] [Related]

  • 23. The von Hippel-Lindau tumor suppressor, hypoxia-inducible factor-1 (HIF-1) degradation, and cancer pathogenesis.
    Pugh CW, Ratcliffe PJ.
    Semin Cancer Biol; 2003 Feb 15; 13(1):83-9. PubMed ID: 12507560
    [Abstract] [Full Text] [Related]

  • 24. Mechanism of regulation of the hypoxia-inducible factor-1 alpha by the von Hippel-Lindau tumor suppressor protein.
    Tanimoto K, Makino Y, Pereira T, Poellinger L.
    EMBO J; 2000 Aug 15; 19(16):4298-309. PubMed ID: 10944113
    [Abstract] [Full Text] [Related]

  • 25. Constitutive activation of hypoxia-inducible genes related to overexpression of hypoxia-inducible factor-1alpha in clear cell renal carcinomas.
    Wiesener MS, Münchenhagen PM, Berger I, Morgan NV, Roigas J, Schwiertz A, Jürgensen JS, Gruber G, Maxwell PH, Löning SA, Frei U, Maher ER, Gröne HJ, Eckardt KU.
    Cancer Res; 2001 Jul 01; 61(13):5215-22. PubMed ID: 11431362
    [Abstract] [Full Text] [Related]

  • 26. Inactivation of VHL by tumorigenic mutations that disrupt dynamic coupling of the pVHL.hypoxia-inducible transcription factor-1alpha complex.
    Miller F, Kentsis A, Osman R, Pan ZQ.
    J Biol Chem; 2005 Mar 04; 280(9):7985-96. PubMed ID: 15611064
    [Abstract] [Full Text] [Related]

  • 27. Nur77 activated by hypoxia-inducible factor-1alpha overproduces proopiomelanocortin in von Hippel-Lindau-mutated renal cell carcinoma.
    Choi JW, Park SC, Kang GH, Liu JO, Youn HD.
    Cancer Res; 2004 Jan 01; 64(1):35-9. PubMed ID: 14729605
    [Abstract] [Full Text] [Related]

  • 28. Ubiquitination of hypoxia-inducible factor requires direct binding to the beta-domain of the von Hippel-Lindau protein.
    Ohh M, Park CW, Ivan M, Hoffman MA, Kim TY, Huang LE, Pavletich N, Chau V, Kaelin WG.
    Nat Cell Biol; 2000 Jul 01; 2(7):423-7. PubMed ID: 10878807
    [Abstract] [Full Text] [Related]

  • 29. Expression of HIF-1 and ubiquitin in conventional renal cell carcinoma: relationship to mutations of the von Hippel-Lindau tumor suppressor gene.
    Hughson MD, He Z, Liu S, Coleman J, Shingleton WB.
    Cancer Genet Cytogenet; 2003 Jun 01; 143(2):145-53. PubMed ID: 12781449
    [Abstract] [Full Text] [Related]

  • 30. Renal cell carcinoma risk in type 2 von Hippel-Lindau disease correlates with defects in pVHL stability and HIF-1alpha interactions.
    Knauth K, Bex C, Jemth P, Buchberger A.
    Oncogene; 2006 Jan 19; 25(3):370-7. PubMed ID: 16261165
    [Abstract] [Full Text] [Related]

  • 31. Loss of pVHL is sufficient to cause HIF dysregulation in primary cells but does not promote tumor growth.
    Mack FA, Rathmell WK, Arsham AM, Gnarra J, Keith B, Simon MC.
    Cancer Cell; 2003 Jan 19; 3(1):75-88. PubMed ID: 12559177
    [Abstract] [Full Text] [Related]

  • 32. The von Hippel-Lindau protein interacts with heteronuclear ribonucleoprotein a2 and regulates its expression.
    Pioli PA, Rigby WF.
    J Biol Chem; 2001 Oct 26; 276(43):40346-52. PubMed ID: 11517223
    [Abstract] [Full Text] [Related]

  • 33. VHL type 2B mutations retain VBC complex form and function.
    Hacker KE, Lee CM, Rathmell WK.
    PLoS One; 2008 Oct 26; 3(11):e3801. PubMed ID: 19030229
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. The von Hippel-Lindau tumor suppressor gene and kidney cancer.
    Kaelin WG.
    Clin Cancer Res; 2004 Sep 15; 10(18 Pt 2):6290S-5S. PubMed ID: 15448019
    [Abstract] [Full Text] [Related]

  • 36. Inactivation of the von Hippel-Lindau (VHL) tumour suppressor gene and allelic losses at chromosome arm 3p in primary renal cell carcinoma: evidence for a VHL-independent pathway in clear cell renal tumourigenesis.
    Clifford SC, Prowse AH, Affara NA, Buys CH, Maher ER.
    Genes Chromosomes Cancer; 1998 Jul 15; 22(3):200-9. PubMed ID: 9624531
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Expression of hypoxia-inducible factors in human renal cancer: relationship to angiogenesis and to the von Hippel-Lindau gene mutation.
    Turner KJ, Moore JW, Jones A, Taylor CF, Cuthbert-Heavens D, Han C, Leek RD, Gatter KC, Maxwell PH, Ratcliffe PJ, Cranston D, Harris AL.
    Cancer Res; 2002 May 15; 62(10):2957-61. PubMed ID: 12019178
    [Abstract] [Full Text] [Related]

  • 39. The HIF and other quandaries in VHL disease.
    Tarade D, Ohh M.
    Oncogene; 2018 Jan 11; 37(2):139-147. PubMed ID: 28925400
    [Abstract] [Full Text] [Related]

  • 40. Selection of mutant CHO cells with constitutive activation of the HIF system and inactivation of the von Hippel-Lindau tumor suppressor.
    Vaux EC, Wood SM, Cockman ME, Nicholls LG, Yeates KM, Pugh CW, Maxwell PH, Ratcliffe PJ.
    J Biol Chem; 2001 Nov 23; 276(47):44323-30. PubMed ID: 11555645
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 31.